New regulatory landscape for biosimilars in the post Brexit transition period
Marie Manley and Chris Boyle from Sidley Austin explore the consequences of Brexit for biopharma companies and the regulatory opportunities that lie ahead.
Source: europeanpharmaceuticalreview.com